Cardiometabolic News and Research

RSS

International congress reflects emerging importance of abdominal obesity

Clinical and basic science researchers from around the world will convene in Hong Kong from January 28 to 30 for the First International Congress on Abdominal Obesity: "Bridging the Gap between Cardiology and Diabetology."

28 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

NicOx S.A. today announced that NicOx and TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration for TPI 1020. This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis announced yesterday.

12 Jan 2010

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Arena Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

22 Dec 2009

Women with gestational glucose intolerance at risk of metabolic syndrome

Women who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

1 Dec 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Football linemen at higher risk of future health problems

For today's athletes, size and strength can mean the difference between championships, scholarships and million-dollar paydays. But new research comparing the signs of metabolic syndrome in professional baseball and football players, presented at the American College of Gastroenterology's 74th Annual Scientific Meeting in San Diego, reveals that the larger professional athletes - specifically football linemen - may encounter future health problems despite their rigorous exercise routines.

27 Oct 2009

Athletes may face future health problems despite their rigorous exercise routines, says study

26 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.

12 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Self-reported diagnosis of heart disease: Less than one in five heart problems are diagnosed before symptoms appear

Clinicians are missing golden opportunities to identify heart disease before patients start displaying symptoms, according to a study of 13,877 people published in the May issue of UK-based IJCP, the International Journal of Clinical Practice.

11 May 2009

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

Yes it's possible to be fit and fat as well!

New research has come up with some surprising revelations about people who are overweight.

12 Aug 2008

Metabolic syndrome and alcohol comsumption

Those who drink in excess of the U.S. Dietary Guidelines (i.e., men who usually drink more than two drinks per day or women who usually drink more than one drink per day) or those who binge drink are at increased risk for the metabolic syndrome, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

31 Jul 2008

Survey reveals most drinkers exceed current safe alcohol guidelines

According to a new study people who drink more than the guidelines for safe alcohol consumption place themselves at risk of developing metabolic syndrome.

30 Jul 2008

Atherotech VAP cholesterol test meets updated ADA, ACC measurement and treatment guidelines for high risk patients

The determination of LDL, non-HDL and apoB are now recognized as valid, accurate and recommended methods of guiding and achieving the best treatment goals for patients with cardiometabolic risk (CMR).

22 Apr 2008

Cardiometabolic News and Research

International congress reflects emerging importance of abdominal obesity

NicOx receives EMEA approval for naproxcinod MAA

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Women with gestational glucose intolerance at risk of metabolic syndrome

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Football linemen at higher risk of future health problems

Athletes may face future health problems despite their rigorous exercise routines, says study

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Self-reported diagnosis of heart disease: Less than one in five heart problems are diagnosed before symptoms appear

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Yes it's possible to be fit and fat as well!

Metabolic syndrome and alcohol comsumption

Survey reveals most drinkers exceed current safe alcohol guidelines

Atherotech VAP cholesterol test meets updated ADA, ACC measurement and treatment guidelines for high risk patients

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News